^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Novaferon (recombinant anti-tumor and anti-virus protein)

    i
    Other names: recombinant anti-tumor and anti-virus protein, recombinant interferon alpha 2b-like protein
    Associations

    News

    Trials
    Company:
    Genova
    Drug class:
    IFNα 2b stimulant
    Related drugs:
    Associations

    News

    Trials
    9ms
    Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov)
    P1/2, N=15, Suspended, M.D. Anderson Cancer Center | Active, not recruiting --> Suspended
    Trial suspension
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • fluorouracil topical • Novaferon (recombinant anti-tumor and anti-virus protein)
    11ms
    Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov)
    P1/2, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • fluorouracil topical • Novaferon (recombinant anti-tumor and anti-virus protein)
    12ms
    A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection (ChiCTR2000029573)
    P4, N=480, Recruiting, The First Affiliated Hospital of Medical College of Zhejiang University; The First Affiliated Hospital of Medical College of Zhejiang University | Phase classification: P3 --> P4 | N=320 --> 480
    Phase classification • Enrollment change
    |
    Novaferon (recombinant anti-tumor and anti-virus protein)
    over1year
    Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (clinicaltrials.gov)
    P1/2, N=15, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2023 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Intron A (interferon α-2b) • fluorouracil topical • Novaferon (recombinant anti-tumor and anti-virus protein)